City Developments stock climbs after JPMorgan lifts target, flags “strategic review”
8 January 2026
1 min read

City Developments stock climbs after JPMorgan lifts target, flags “strategic review”

SINGAPORE, Jan 8, 2026, 15:50 (SGT) — Regular session

City Developments’ shares rose 1.7% to S$8.89 in afternoon trade on Thursday, hovering near the day’s high of S$8.95, after a bullish broker call kept focus on asset sales and potential payout upside. 1

The move matters now because property developers are back in play at the start of 2026, with investors hunting for balance-sheet repair and cash returns after a long stretch where higher rates punished the sector’s valuations.

For City Developments, the near-term story is less about a new project launch and more about whether management can turn divestments into cleaner numbers — and, eventually, dividends that show up in cash.

JPMorgan analysts Mervin Song and Terence Khi raised their target price to S$10.75 from S$8.20 in a Jan. 6 note, pointing to a potential “strategic review” and saying the stock still trades at about a 20% discount to book value. They estimated a dividend of 23 Singapore cents a share, above consensus estimates of 17.3 cents, and forecast FY2025 earnings of S$83.9 million and FY2026 earnings of S$200 million. They also expect a narrowing of the discount to RNAV — revalued net asset value, a common property-sector yardstick that marks assets closer to market prices. 2

The stock was already in motion on Wednesday, when it led gainers on Singapore’s Straits Times Index with a 4.2% rise to S$8.74 as the benchmark edged up 0.2% and tracked Wall Street’s gains. “Wall Street closed up at record highs,” Neil Wilson, UK investor strategist at Saxo Markets, was quoted as saying. 3

Technicians will note the stock’s push toward the top of its 52-week range of S$4.32 to S$8.95, a level that has started to act like a magnet this week as volumes picked up. 4

But the broker case leans heavily on two things that can wobble: interest-rate tailwinds and the pace of non-core asset sales. A hotter run of inflation or a stumble in residential sales would leave the stock looking expensive on near-term earnings, and the “strategic review” talk could fade back into the usual sell-side noise.

Stock Market Today

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
Singtel stock rebounds in Singapore trade after sharp drop; Optus shake-up in focus
Previous Story

Singtel stock rebounds in Singapore trade after sharp drop; Optus shake-up in focus

OCBC stock back near record highs as dividend buyers crowd into Singapore banks
Next Story

OCBC stock back near record highs as dividend buyers crowd into Singapore banks

Go toTop